Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lovenox ANDA filings

Executive Summary

Two generic firms - Amphastar and Teva - have filed Paragraph IV certifications against Lovenox (enoxaparin), Aventis announces. The certifications challenge the product's 5,389,618 patent, which expires in February 2012, but not its 4,692,435 patent, which expires in December 2004. Aventis is seeking a re-issuance of the '618 patent as part of its patent defense of the low-molecular weight heparin (1"The Pink Sheet" May 5, 2003, p. 10). ANDA filings for the product attracted attention in early April when FDA posted, and then removed, Lovenox from the list of products which have Paragraph IV certifications. Amphastar said that its ANDA was approved for filing April 21...

You may also be interested in...



Aventis Lovenox Generics Defense Includes Re-Issuance Of Patent

Aventis plans to file an application for the re-issuance of a patent relating to its low molecular weight heparin agent Lovenox, the company told analysts April 30

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel